ICPT · Intercept Pharmaceuticals, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Revenue | $285.71M | $363.47M | $312.69M | $252.00M | $24.95M | $130.96M |
| Cost of Revenue | $984.0K | $3.10M | $5.32M | $1.37M | $2.52M | $1.37M |
| Gross Profit | $284.73M | $360.37M | $307.37M | $250.63M | $22.43M | $129.59M |
| R&D | $176.64M | $185.27M | $191.49M | $242.80M | $207.30M | $191.50M |
| SG&A | $176.30M | $230.85M | $332.49M | $317.42M | $255.47M | $273.70M |
| Total Operating Expenses | $353.93M | $419.14M | $543.93M | $466.57M | $465.29M | $466.57M |
| D&A | $592.0K | $2.98M | $3.12M | $3.66M | $4.58M | $4.60M |
| Operating Income | ($68.22M) | ($55.67M) | ($231.24M) | ($312.43M) | ($285.49M) | ($335.61M) |
| Interest Expense | $21.39M | $54.42M | $48.05M | $41.14M | $30.52M | $29.27M |
| Income Tax | - | - | - | - | - | - |
| Net Income | $221.82M | ($91.43M) | ($274.88M) | ($344.68M) | ($309.24M) | ($360.37M) |
| EPS - Basic | $6.56 | ($8.34) | - | - | - | - |
| EPS - Diluted | $6.56 | ($8.34) | - | - | - | - |
Balance Sheet
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $50.52M | $84.71M | $58.15M | $70.06M | $43.25M | $70.01M |
| Accounts Receivable | $26.86M | $47.62M | $41.55M | $38.04M | $25.69M | $16.50M |
| Inventory | $6.46M | $8.62M | $9.03M | $8.46M | $7.11M | $3.48M |
| Accounts Payable | $14.23M | $18.13M | $24.59M | $18.98M | $11.77M | $6.96M |
| Current Assets | $540.13M | $502.29M | $545.74M | $721.32M | $482.43M | $448.31M |
| Total Assets | $553.71M | $527.02M | $580.49M | $754.89M | $509.17M | $484.35M |
| Current Liabilities | $230.08M | $166.82M | $179.08M | $162.00M | $114.20M | $104.03M |
| Long-term Debt | $223.10M | $539.78M | $560.58M | $532.08M | $371.25M | $355.68M |
| Total Liabilities | $460.63M | $710.99M | $747.34M | $703.33M | $490.04M | $467.96M |
| Stockholders' Equity | $93.08M | ($183.96M) | ($166.85M) | $51.56M | $19.13M | $16.39M |
| Retained Earnings | ($2.14B) | ($2.49B) | ($2.40B) | ($2.12B) | ($1.78B) | ($1.47B) |
Cash Flow
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($26.78M) | ($41.64M) | ($170.03M) | ($236.61M) | ($240.71M) | ($342.44M) |
| Investing Cash Flow | $261.85M | $70.73M | $162.82M | ($188.99M) | ($48.07M) | ($60.13M) |
| Financing Cash Flow | ($267.32M) | $1.12M | ($693.0K) | $457.52M | $263.55M | $414.38M |
| CapEx | $568.0K | $397.0K | $3.89M | $1.14M | $167.0K | $10.39M |
| Free Cash Flow | ($27.35M) | ($42.04M) | ($173.92M) | ($237.75M) | ($240.88M) | ($352.83M) |
Ratios
| Metric | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 99.7% | 99.1% | 98.3% | 99.5% | 89.9% | 99.0% |
| Operating margin | -23.9% | -15.3% | -74.0% | -124.0% | -1144.2% | -256.3% |
| EBITDA margin | -23.7% | -14.5% | -73.0% | -122.5% | -1125.8% | -252.8% |
| Net margin | 77.6% | -25.2% | -87.9% | -136.8% | -1239.4% | -275.2% |
| Free cash flow margin | -9.6% | -11.6% | -55.6% | -94.3% | -965.4% | -269.4% |
| FCF / Net income | -0.12 | 0.46 | 0.63 | 0.69 | 0.78 | 0.98 |
| R&D / Revenue | 61.8% | 51.0% | 61.2% | 96.3% | 830.8% | 146.2% |
| SG&A / Revenue | 61.7% | 63.5% | 106.3% | 126.0% | 1023.9% | 209.0% |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | 40.1% | -17.3% | -47.4% | -45.7% | -60.7% | -74.4% |
| Return on equity | 238.3% | 49.7% | 164.7% | -668.6% | -1616.5% | -2199.2% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 2.35 | 3.01 | 3.05 | 4.45 | 4.22 | 4.31 |
| Quick ratio | 2.32 | 2.96 | 3.00 | 4.40 | 4.16 | 4.28 |
| Cash ratio | 0.22 | 0.51 | 0.32 | 0.43 | 0.38 | 0.67 |
| Leverage | ||||||
| Debt / Equity | 2.40 | -2.93 | -3.36 | 10.32 | 19.41 | 21.71 |
| Debt / Assets | 0.40 | 1.02 | 0.97 | 0.70 | 0.73 | 0.73 |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | -3.2x | -1.0x | -4.8x | -7.6x | -9.4x | -11.5x |
| Equity multiplier | 5.95 | -2.86 | -3.48 | 14.64 | 26.62 | 29.56 |
| Liabilities / Assets | 0.83 | 1.35 | 1.29 | 0.93 | 0.96 | 0.97 |
| Efficiency | ||||||
| Asset turnover | 0.52 | 0.69 | 0.54 | 0.33 | 0.05 | 0.27 |
| Inventory turnover | 0.15 | 0.36 | 0.59 | 0.16 | 0.35 | 0.39 |
| Days sales outstanding | 34d | 48d | 48d | 55d | 376d | 46d |
| Days inventory outstanding | 2397d | 1015d | 619d | 2253d | 1030d | 926d |
| Days payable outstanding | 5280d | 2135d | 1687d | 5052d | 1705d | 1854d |
| Cash conversion cycle | -2849d | -1072d | -1019d | -2744d | -299d | -882d |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | -21.4% | 16.2% | 24.1% | 910.0% | -80.9% | 424.9% |
| Revenue CAGR (3y) | 4.3% | 144.2% | 33.7% | 116.2% | - | - |
| Revenue CAGR (5y) | 16.9% | 70.9% | - | - | - | - |
| Gross profit growth (YoY) | -21.0% | 17.2% | 22.6% | 1017.3% | -82.7% | - |
| Operating income growth (YoY) | -22.5% | 75.9% | 26.0% | -9.4% | 14.9% | 16.6% |
| Net income growth (YoY) | - | 66.7% | 20.3% | -11.5% | 14.2% | 12.7% |
| EPS growth (YoY) | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | 34.9% | 75.8% | 26.8% | 1.3% | 31.7% | -1.5% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | - | -10.3% | - | 169.5% | 16.7% | -94.8% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2021-12-31.
Product / service
$363.47M totalProduct$363.47M · 100.0%
Stability scores
Altman Z′
FY 2022 · bankruptcy risk
-2.65
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2022 · 9-point quality
4/9
Neutral
- ✓Net income positive
- ✗Operating cash flow positive
- ✓ROA improved YoY
- ✗Cash flow > net income
- ✓Long-term debt decreased
- ✗Current ratio improved
- ✗No share dilution
- ✓Gross margin improved
- ✗Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing INTERCEPT PHARMACEUTICALS against the 5 most active filers in the same SIC group.